menu search

CHNXF / ChitogenX confirms soft-tissue residency properties of its chitosan/PRP-based biopolymer matrix

ChitogenX confirms soft-tissue residency properties of its chitosan/PRP-based biopolymer matrix
ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has successfully confirmed soft-tissue residency properties of its chitosan/platelet-rich plasma (PRP)-based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The Montreal-based clinical-stage regenerative medicine company noted that the meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. Read More
Posted: Feb 14 2023, 07:28
Author Name: Proactive Investors
Views: 111027

CHNXF News  

ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform

By Proactive Investors
September 29, 2023

ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors that it made significant progress in deleveraging its balance sheet and improving its working cap more_horizontal

ChitogenX receives notice of allowance for key patent in the US and Canada

By Proactive Investors
September 28, 2023

ChitogenX receives notice of allowance for key patent in the US and Canada

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) told investors it has received a notice of allowance for a key patent in the US and Canada. The company noted th more_horizontal

ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial

By Proactive Investors
September 26, 2023

ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has concluded the enrolment of 20 subjects in its US multi-site rotator cuff tear repair Phase I/II clin more_horizontal

ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial

By Proactive Investors
June 30, 2023

ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has noted that patient recruitment for its rotator cuff repair Phase I/II trial reached an important milestone� more_horizontal

ChitogenX pursuing new strategic development partnerships

By Proactive Investors
June 15, 2023

ChitogenX pursuing new strategic development partnerships

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has partnered with Bruder Consulting & Venture Group (BCVG) as its exclusive advisory firm for the pur more_horizontal

ChitogenX raises $3.9M to advance tissue repair research

By Proactive Investors
May 5, 2023

ChitogenX raises $3.9M to advance tissue repair research

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has closed its amended non-brokered private placement offering for gross proceeds of $3.86 million. The more_horizontal

ChitogenX announces non-brokered private placement for gross proceeds of $2.5M

By Proactive Investors
April 4, 2023

ChitogenX announces non-brokered private placement for gross proceeds of $2.5M

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) has announced a non-brokered private placement offering of 12,500,000 units at a price of $0.20 each for gross p more_horizontal

ChitogenX obtains $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec

By Proactive Investors
February 16, 2023

ChitogenX obtains $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec

ChitogenX Inc (CSE:CHGX, OTCQB:CHNXF) said it has obtained, in partnership with Polytechnique Montréal, a $3,472,000 grant from The Natural Sciences more_horizontal


Search within

Pages Search Results: